Literature DB >> 30967440

Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?

Christopher T Szlenk1, Jeevan B Gc1, Senthil Natesan2.   

Abstract

The ligand-binding sites of many G protein-coupled receptors (GPCRs) are situated around and deeply embedded within the central pocket formed by their seven transmembrane-spanning α-helical domains. Generally, these binding sites are assumed accessible to endogenous ligands from the aqueous phase. Recent advances in the structural biology of GPCRs, along with biophysical and computational studies, suggest that amphiphilic and lipophilic molecules may gain access to these receptors by first partitioning into the membrane and then reaching the binding site via lateral diffusion through the lipid bilayer. In addition, several crystal structures of class A and class B GPCRs bound to their ligands offer unprecedented details on the existence of lipid-facing allosteric binding sites outside the transmembrane helices that can only be reached via lipid pathways. The highly organized structure of the lipid bilayer may direct lipophilic or amphiphilic drugs to a specific depth within the bilayer, changing local concentration of the drug near the binding site and affecting its binding kinetics. Additionally, the constraints of the lipid bilayer, including its composition and biophysical properties, may play a critical role in "pre-organizing" ligand molecules in an optimal orientation and conformation to facilitate receptor binding. Despite its clear involvement in molecular recognition processes, the critical role of the membrane in binding ligands to lipid-exposed transmembrane binding sites remains poorly understood and warrants comprehensive investigation. Understanding the mechanistic basis of the structure-membrane interaction relationship of drugs will not only provide useful insights about receptor binding kinetics but will also enhance our ability to take advantage of the apparent membrane contributions when designing drugs that target transmembrane proteins with improved efficacy and safety. In this minireview, we summarize recent structural and computational studies on membrane contributions to binding processes, elucidating both lipid pathways of ligand access and binding mechanisms for several orthosteric and allosteric ligands of class A and class B GPCRs.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2019        PMID: 30967440      PMCID: PMC6776015          DOI: 10.1124/mol.118.115113

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  153 in total

1.  Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor.

Authors:  P Ghanouni; J J Steenhuis; D L Farrens; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 2.  Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.

Authors:  Peter Keov; Patrick M Sexton; Arthur Christopoulos
Journal:  Neuropharmacology       Date:  2010-07-15       Impact factor: 5.250

Review 3.  On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.

Authors:  Georges Vauquelin
Journal:  Expert Opin Drug Discov       Date:  2015-07-13       Impact factor: 6.098

Review 4.  Functional and structural perspectives on allosteric modulation of GPCRs.

Authors:  Christopher J Langmead; Arthur Christopoulos
Journal:  Curr Opin Cell Biol       Date:  2013-12-22       Impact factor: 8.382

Review 5.  Interaction of G protein coupled receptors and cholesterol.

Authors:  Gerald Gimpl
Journal:  Chem Phys Lipids       Date:  2016-04-20       Impact factor: 3.329

6.  Noncompetitive inhibitors reach their binding site in the acetylcholine receptor by two different paths.

Authors:  M Blanton; E McCardy; T Gallaher; H H Wang
Journal:  Mol Pharmacol       Date:  1988-06       Impact factor: 4.436

7.  In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor.

Authors:  Ariuna Bazarsuren; Ulla Grauschopf; Manfred Wozny; Dietmar Reusch; Eike Hoffmann; Wolfgang Schaefer; Steffen Panzner; Rainer Rudolph
Journal:  Biophys Chem       Date:  2002-05-02       Impact factor: 2.352

Review 8.  The expanding role of quantitative structure-activity relationships (QSAR) in toxicology.

Authors:  C Hansch; D Hoekman; A Leo; L Zhang; P Li
Journal:  Toxicol Lett       Date:  1995-09       Impact factor: 4.372

9.  Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators.

Authors:  Gaojie Song; Dehua Yang; Yuxia Wang; Chris de Graaf; Qingtong Zhou; Shanshan Jiang; Kaiwen Liu; Xiaoqing Cai; Antao Dai; Guangyao Lin; Dongsheng Liu; Fan Wu; Yiran Wu; Suwen Zhao; Li Ye; Gye Won Han; Jesper Lau; Beili Wu; Michael A Hanson; Zhi-Jie Liu; Ming-Wei Wang; Raymond C Stevens
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

10.  The Free Energy Landscape of GABA Binding to a Pentameric Ligand-Gated Ion Channel and Its Disruption by Mutations.

Authors:  Federico Comitani; Vittorio Limongelli; Carla Molteni
Journal:  J Chem Theory Comput       Date:  2016-06-09       Impact factor: 6.006

View more
  14 in total

Review 1.  Ligand binding at the protein-lipid interface: strategic considerations for drug design.

Authors:  Jian Payandeh; Matthew Volgraf
Journal:  Nat Rev Drug Discov       Date:  2021-07-13       Impact factor: 84.694

Review 2.  New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery.

Authors:  Julia Park; Christopher J Langmead; Darren M Riddy
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-20

3.  A Retrospective Look at the Impact of Binding Site Environment on the Optimization of TRPA1 Antagonists.

Authors:  Elisia Villemure; Jack A Terrett; Robin Larouche-Gauthier; Martin Déry; Huifen Chen; Rebecca M Reese; Shannon D Shields; Jun Chen; Steven Magnuson; Matthew Volgraf
Journal:  ACS Med Chem Lett       Date:  2021-07-19       Impact factor: 4.632

4.  Membrane Lipids Are an Integral Part of Transmembrane Allosteric Sites in GPCRs: A Case Study of Cannabinoid CB1 Receptor Bound to a Negative Allosteric Modulator, ORG27569, and Analogs.

Authors:  Peter Obi; Senthil Natesan
Journal:  J Med Chem       Date:  2022-09-06       Impact factor: 8.039

5.  Interaction With the Lipid Membrane Influences Fentanyl Pharmacology.

Authors:  Katy J Sutcliffe; Robin A Corey; Norah Alhosan; Damiana Cavallo; Sam Groom; Marina Santiago; Chris Bailey; Steven J Charlton; Richard B Sessions; Graeme Henderson; Eamonn Kelly
Journal:  Adv Drug Alcohol Res       Date:  2022-03-21

6.  An allosteric modulator binds to a conformational hub in the β2 adrenergic receptor.

Authors:  Xiangyu Liu; Jonas Kaindl; Magdalena Korczynska; Anne Stößel; Daniela Dengler; Markus Stanek; Harald Hübner; Mary J Clark; Jake Mahoney; Rachel Ann Matt; Xinyu Xu; Kunio Hirata; Brian K Shoichet; Roger K Sunahara; Brian K Kobilka; Peter Gmeiner
Journal:  Nat Chem Biol       Date:  2020-06-01       Impact factor: 15.040

Review 7.  On the Rational Drug Design for Hypertension through NMR Spectroscopy.

Authors:  Eleni Chontzopoulou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

8.  Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors.

Authors:  Gian Marco Elisi; Laura Scalvini; Alessio Lodola; Marco Mor; Silvia Rivara
Journal:  J Chem Inf Model       Date:  2021-12-21       Impact factor: 4.956

9.  FRET sensors reveal the retinal entry pathway in the G protein-coupled receptor rhodopsin.

Authors:  He Tian; Kathryn M Gunnison; Manija A Kazmi; Thomas P Sakmar; Thomas Huber
Journal:  iScience       Date:  2022-03-11

10.  Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting β2-Adrenergic Receptor Agonists.

Authors:  Christopher T Szlenk; Jeevan B Gc; Senthil Natesan
Journal:  Mol Pharmacol       Date:  2021-08-01       Impact factor: 4.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.